Latest news with #GLP-1RAs
Yahoo
21-05-2025
- Business
- Yahoo
Novo Nordisk and Eli Lilly Lead, but New Entrants Eye GLP-1RA Market Opportunities
Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity. Discover insights on unmet needs, pipeline analysis, and competitive landscapes, highlighting major players like Novo Nordisk and Eli Lilly and potential new entrants. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview" report has been added to report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory are being investigated in different diseases in the metabolic, neurologic, and cardiologic Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new Scope Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation. Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing. Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas. Overview of current major players in the GLP-1RAs space and potential future players. GLP-1RAs global market outlook and deals overview. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future. Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface 2 Executive Summary3 GLP-1R Agonists Overview3.1 What Are GLP-1R Agonists3.2 GLP-1R in the Body3.3 History of GLP-1R Agonists4 Industry Trends4.1 Oral GLP-1Ras4.2 Lower Dosing Frequency4.3 Combination and Dual/Triple Agonists4.4 Repurposing GLP-1Ras5 Marketed Products5.1 Global GLP-1RA Marketed Landscape5.2 Marketed GLP-1Ras5.3 Challenges and Opportunities in GLP-1RA Repurposing5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs6 Pricing and Reimbursement Assessment Case Study: Ozempic7 Pipeline Analysis7.1 Top 20 Indications with GLP-1RAs in Development7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets7.3 GLP-1RA Pipeline Candidates7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease7.7 GLP-1RA Opportunities Beyond Planned Label Expansions7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome8 Opportunities and Challenges8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis8.2 Opportunities: GLP-1RAs in Liver Diseases8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson's Disease8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease8.10 Opportunities: GLP-1RAs in Other Diseases9 Companies9.1 Current Major Player: Novo Nordisk9.2 Current Major Player: Eli Lilly9.3 Potential Future Players9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space10 Market Outlook and Deals10.1 GLP-1RA Global Market10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1RasCompany Coverage Includes: Novo Nordisk AS Eli Lilly and Co Shanghai Minwei Biotechnology Co Ltd Metsera Inc Sihuan Pharmaceutical Holdings Group Ltd Hanmi Pharmaceuticals Co Ltd Jiangsu Hengrui Medicine Co Ltd AstraZeneca Plc PegBio Co Ltd Beijing QL Biopharmaceutical Co Ltd Sciwind Biosciences Co Ltd U.S. National Institutes of Health Boehringer Ingelheim International GmbH i2O Therapeutics Inc Zhejiang Doer Biologics Corp CSPC Pharmaceutical Group Ltd Peptron Inc Carmot Therapeutics Inc Amogen Pharma Pvt Ltd BioLingus AG The United Laboratories International Holdings Ltd Tonghua Dongbao Pharmaceutical Co Ltd Annovis Bio Inc ImmunoForge Co Ltd Biogenomics Ltd China Pharmaceutical University Zhejiang Heze Pharmaceutical Technology Co Ltd Zhuhai United Laboratories Co Ltd Hangzhou Jiuyuan Gene Engineering Co Ltd Structure Therapeutics Inc Altimmune Inc Chia Tai Tianqing Pharmaceutical Group Co Ltd Gmax Biopharm LLC Guangzhou Dazhou Biomedical Technology Co Ltd Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd Huadong Medicine Co Ltd Innovent Biologics Inc Merck & Co Inc Neuraly Inc Onegene Biotechnology Inc Protheragen Inc RenaissThera Pvt Ltd Sekkei Inc Uni-Bio Science Group Ltd HEC Pharma Co Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Cascade Pharmaceuticals Inc D&D Pharmatech Co Ltd Huons Global Co Ltd Immunwork Inc Leto Laboratories Co Ltd MetaVia Inc Pfizer Inc Qilu Regor Therapeutics Inc Sanofi Xintrum Pharmaceuticals Ltd Gan & Lee Pharmaceuticals Co Ltd Adocia SAS AnyGen Co Ltd Ascendis Pharma AS AULBIO Co Ltd BrightGene Bio-Medical Technology Co Ltd Camurus AB HK inno.N Corp Hybio Pharmaceutical Co Ltd IGC Pharma Inc Lancaster University Laxxon Medical GmbH Poolbeg Pharma Plc ProGen Co Ltd Septerna Inc Shanghai Innogen Pharmaceutical Technology Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd Sun Pharmaceutical Industries Ltd Suzhou Wingtech Pharmaceutical Technology Co Ltd Theertha Biopharma Pvt Ltd Verdiva Bio Ltd Vivani Medical Inc Yunovia Co Ltd Adare Pharma Solutions Amgen Inc Apeloa Pharmaceutical Co Ltd ApicHope Pharmaceutical Co Ltd Arecor Therapeutics Plc Biolexis Therapeutics Inc Biomea Fusion Inc Biomed Industries Inc BioNxt Solutions Inc California Institute for Biomedical Research China Medical System Holdings Ltd Chongqing Chenan BioPharm Co Ltd CinFina Pharma LLC Crinetics Pharmaceuticals Inc CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd Daewoong Therapeutics Inc Diabetology (Products) Ltd Dx&Vx Efil Bioscience Inc Entera Bio Ltd Gilead Sciences Inc Guangzhou BeBetter Medicine Technology Co Ltd HangZhou HuiSheng Biotech Pharmaceutical Co Ltd Hepagene Therapeutics Inc HighField Biopharmaceuticals, Inc. Hua Medicine Shanghai Ltd INVENT Pharmaceuticals Inc Inventage Lab Inc iX Biopharma Ltd Jiangsu Normal University Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd Livzon Pharmaceutical Group Inc MeiraGTx Holdings Plc MindRank Ltd Niedlfree Technologies Pvt Ltd OPKO Health Inc Remedium Bio Inc Scohia Pharma Inc Shandong New Era Pharmaceutical Co Ltd SN BioScience Co Ltd Tharimmune Inc Viking Therapeutics Inc vTv Therapeutics Inc Youngene Therapeutics Co Ltd Zealand Pharma AS 4Moving Biotech Abaxys Therapeutics SA Aerami Therapeutics Holdings Inc AI Proteins Inc Akrikhin Alphamab Oncology Aprilbio Co Ltd Ascletis Pharma Inc Beijing Eastern Biotech Co Ltd Beijing SL Pharmaceutical Co Ltd Biora Therapeutics Inc Bostal Drug Delivery Co Ltd Bristol-Myers Squibb Co Chengdu Brilliant Pharmaceutical Co Ltd China Resources Double-Crane Pharmaceutical Co Ltd Closed Loop Medicine Ltd Coya Therapeutics Inc Delpor Inc Duke University Enteris BioPharma Inc G2GBIO Inc GlyTech Inc Gubra ApS Halo Therapeutics Ltd HEC Pharm Group Hualan Biological Engineering Inc Iconovo AB Icure Pharmaceutical Inc Imagine Pharma LLC Immupharma Plc Imperial College London Innopharmax Inc Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd Kailera Therapeutics Inc Kariya Pharmaceuticals IVS Kunming Yinnuo Medical Technology Co. Ltd. Lanzhou Institute of Biological Products Co Ltd Lepu Medical Technology (Beijing) Co Ltd Mapi Pharma Ltd MBX Biosciences Inc Metaphore Biotechnologies Inc Nanexa AB National Institute of Biomedical Imaging and Bioengineering NutriBand Inc Oramed Pharmaceuticals Inc Original BioMedicals Co Ltd Pep2Tango Therapeutics Inc ProLynx LLC Qilu Pharmaceutical Co Ltd QuiaPEG Pharmaceuticals AB Rani Therapeutics LLC Rivus Pharmaceuticals Inc Rose Pharma Inc R-Pharm Sail Biomedicines Inc Shandong Boan Biotechnology Co Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd Sino Biopharmaceutical Ltd Syracuse University Terns Pharmaceuticals Inc Terry Suzhou Pharmaceutical Co Ltd The University of Adelaide Twist Bioscience Corp University of Padova University of Ulster Vanderbilt University Virtici LLC Wuxi Hebang Biotechnology Co Ltd Yichang Humanwell Pharmaceutical Co Ltd Yonsei University College of Medicine Zhejiang HuaYang Pharmaceutical Co Ltd Zhongshan Wanhan Pharmaceutical Co Ltd For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
17-05-2025
- Health
- New York Post
Weight loss, diabetes drugs can cause mood changes: What to know about behavioral side effects
GLP-1 receptor agonists (GLP-1 RAs), medications that help control type 2 diabetes and obesity, can have a profound impact on physical wellness – but what about mental health? Some examples of these medications include semaglutides, such as Ozempic and Wegovy, and liraglutide, like Victoza and Saxenda. Advertisement Various studies have pointed toward GLP-1 RAs causing mental health complications, such as anxiety and depression. The National Institutes of Health (NIH) published research in June 2024 that considered the correlation between semaglutide therapy and 'exacerbating mood disturbances.' The study highlighted the association of negative mood changes in patients with type 2 diabetes with a history of depression, warning healthcare providers to be aware of this 'potential risk.' But a more recent study, published in the journal Diabetes, Obesity and Metabolism, suggested that these mood changes were linked to genetic variations across diverse populations and ancestries within the U.K. Biobank. Advertisement While GLP-1 RA variants had 'consistent cardiometabolic effects' across all groups, the researchers said the negative impacts on mental health were 'more varied,' concluding that any behavioral changes are 'likely not acting directly through [the medications].' 5 Nazario noted that GLP-1 RAs can affect mood in many different ways. tmc_photos – Doctors weigh in on medications and mood Dr. Brett Osborn, a Florida neurosurgeon who often prescribes GLP-1 RAs to his patients, believes that there is 'no consistent causal relationship' between these medications and mental illness. 'Researchers assayed genetic markers across almost half a million people from different backgrounds in search of a link between the gene behind GLP-1 receptors and mental health problems like depression, anxiety or suicidal ideation — and they didn't find it,' he summarized. Advertisement People who are obese or battling type 2 diabetes are 'often already depressed' without the medication, the doctor pointed out. 5 Various studies have pointed toward GLP-1 RAs causing mental health complications, such as anxiety and depression. nazif – 'These conditions take a toll – physically, emotionally and socially,' he said. 'So, yes, a large portion of patients starting GLP-1 drugs are already dealing with mental health struggles. But that's not because of the drug — that's because of the disease.' Once these individuals begin dropping weight, blood sugar stabilizes and energy improves, which usually lifts their mood as well. Advertisement 'GLP-1 drugs help people reclaim their health,' Osborn noted. 'They reduce inflammation. They lower blood sugar. They shrink waistlines.' 5 People who are obese or battling type 2 diabetes are 'often already depressed' without the medication, the doctor pointed out. K KStock – 'And when people look and feel better, when their bodies finally start working for them instead of against them, they often smile more, not less.' Dr. Muhammad Ghanem, a bariatric surgeon at Orlando Health Weight Loss and Bariatric Surgery Institute, shared in a separate interview with Fox News Digital that while some of his patients have reported mood changes, others 'don't have that at all.' 'Depression or mood changes are very common regardless, especially nowadays, and so it's hard to [determine] whether this is related to the GLP-1 agonist medications, or whether it just happens to be that they started suffering from these after they started that medication,' he said. 'It's really hard to tell whether it's a personality change that can happen because of weight loss or if it's a side effect because of mood changes,' he added. 'I don't think we have enough data to reach that conclusion yet.' Patients who lose weight with GLP-1 RAs can experience a 'big boost' in confidence, as well as a change in personality and even relationships, according to Ghanem. 5 Once these individuals begin dropping weight, blood sugar stabilizes and energy improves, which usually lifts their mood as well. Tinnakorn – Advertisement 'It really depends on the person and the support system they have,' he said. 'You need proper, randomized controlled trials to reach a conclusion, and better studies to determine whether this is related to the medication itself or just weight loss.' 'It's important for all doctors who prescribe these drugs to be aware and check the patient's history.' For those who are interested in these medications or are experiencing mood changes while taking them, the surgeon stressed the importance of keeping in close contact with medical providers. 'Just like any other medication, they can have potential side effects,' he said. Advertisement Ghanem recommended seeking out professionals and practices who take a 'holistic approach' to weight loss, offering mental health support in addition to medication. 5 For those who are interested in these medications or are experiencing mood changes while taking them, the surgeon stressed the importance of keeping in close contact with medical providers. alones – Dr. Brunilda Nazario, MD, chief physician editor of medical affairs at WebMD, told Fox News Digital that 'obesity is complicated.' 'Obesity specialists … are cautiously excited about how well these drugs work,' she said. Advertisement 'With current studies showing conflicting results on mood disorders and the use of GLP-1 drugs, it's important for all doctors who prescribe these drugs to be aware and check the patient's history before prescribing [them].' Nazario stressed that it's 'vital' for GLP-1 RA users to listen to their bodies, urging them to pay attention to their feelings and know the symptoms of mood disorders. 'Don't be afraid to ask for help if you feel something is not right — your health depends on it,' he added. Advertisement Nazario noted that GLP-1 RAs can affect mood in many different ways. 'They are not all negative — they have the potential to improve mood as well,' she said. 'Just seeing great results can boost self-esteem, confidence and body image.'
Yahoo
14-05-2025
- Health
- Yahoo
Weight-loss drugs' impact on cancer risk revealed in new study
Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, meningioma, adenocarcinoma of esophagus; stomach, colorectal, liver or bile duct, gallbladder, pancreas, uterus, ovary, renal-cell kidney, thyroid, and postmenopausal breast cancer, according to the Centers for Disease Control and Prevention (CDC). Semaglutide Found To Have Shocking Benefit For Liver Disease Patients In New Study Researchers at Clalit Health Services in Tel Aviv, Israel, conducted an observational study of the medical records of 6,356 participants aged 24 and older who had obesity and diabetes, with no history of obesity-related cancer. Between 2010 and 2018, half of the participants took GLP-1 receptor agonists (GLP-1 RAs) — injectable medications for obesity and type 2 diabetes — with at least six drug purchases within 12 months. The other half underwent bariatric metabolic surgery (BMS). Read On The Fox News App After adjusting for other factors, the researchers determined that ORC occurred in 5.62 cases per 1,000 person-years in those who had the surgery, and in 5.89 cases per 1,000 person-years among those who took GLP-1s. Overall, the study determined that "the direct effect of GLP1-RAs compared to BMS on the risk for ORC beyond their effects on weight-loss is estimated as 41% relative risk reduction." Here's Why Belly Fat Is More Common As We Age, And 3 Ways To Prevent It The findings were published in the journal eClinicalMedicine. "The results point at the existence of additional pathways beyond weight loss in which GLP-1RAs contribute to the decreased risk for obesity-related cancer," lead study author Yael Wolff Sagy, PhD, head of research at Clalit Health Services, told Fox News Digital. Niketa Patel, professor of molecular medicine with the USF Health Morsani College of Medicine in Tampa, Florida, noted that obesity is associated with chronic inflammation. "GLP1-RAs are shown to reduce inflammation and thus decrease the risk of developing ORC," she told Fox News Digital. (Patel was not involved in the study.) "Bottom line: Obesity can cause certain cancers, and treatment of obesity with GLP1-RA reduces the risk of only obesity-related cancers." Dr. Britta Reierson, MD, medical director of knownwell, a provider of metabolic health services, said there are several ways in which GLP-1 RAs could have cancer mitigation properties. "First, the anti-inflammatory properties of these medications address a known risk factor for various cancers," the Minnesota-based doctor, who also was not part of the research, told Fox News Digital. "Second, the metabolic regulation and improvement in metabolic health from these medications, including lowering blood glucose levels and decreasing insulin resistance, can reduce cancer risk." Emerging evidence also suggests that GLP-1 RAs may have direct anti-tumor effects, Reierson noted — "potentially through modulation of immune responses and epigenetic changes (changes that occur to gene expression and are passed down to future generations)." First Glp-1 Pill For Weight Loss, Diabetes Shows Success In Late-phase Trial Research suggests that GLP-1 medications help reduce inflammation not just through weight loss, but also in other organs of the body, such as the heart, according to Dr. Susan Savery, MD, a board-certified obesity medicine and primary care physician with PlushCare, a virtual health platform offering primary care, therapy and weight management services. "Over time, chronic inflammation can be a risk factor for cancer development, as it may damage cell DNA," San Francisco-based Savery, who was not involved in the study, told Fox News Digital. "Our fat cells (adipose tissue) naturally produce inflammatory cells, and GLP-1 medications, similar to bariatric surgery, help reduce this inflammation by decreasing the amount of adipose tissue through weight loss." The study did have some limitations, the researchers acknowledged. "First, it is an observational study. It means that our comparison groups (persons who had surgery versus those who received GLP1-RAs) may still have some residual differences, despite our methodological efforts," Sagy told Fox News Digital. "However, only this type of real-life observational study can provide the long follow-up period that is necessary to evaluate the risk of developing cancer, which often has very long latency periods." Another limitation is that the primary drug included in the study was liraglutide (Saxenda, Victoza), with smaller numbers of people taking exenatide (Byetta) and dulaglutide (Trulicity). "It will be important to evaluate the comparative effectiveness of the newer GLP1-RA drugs, which are expected to have a larger effect," Sagy said. "Although the direction of the results is promising, we should wait and see if and how clinical guidelines will consider it." Click Here To Sign Up For Our Health Newsletter Reierson agreed that much more research is needed before GLP-1 RAs could ever be considered as cancer prevention options. "Larger, randomized, controlled trials are necessary to confirm the observed effects and better understand the underlying mechanisms," she said. "It will also be important to investigate the impact of GLP-1 RAs on different types of cancer and assess the long-term safety and potential side effects of using GLP-1 RAs as a cancer therapy." Savery agrees that it's likely too early to predict FDA approval for cancer therapy, but noted that "weight reduction plays an important role in cancer prevention, and GLP-1s seem to offer an additional benefit through inflammation reduction." For more Health articles, visit While GLP-1 RAs are "wonderful tools" that can support people on weight-loss journeys, Savery pointed out that maintaining a healthy lifestyle through nutritious eating and regular physical activity is "the foundation for cancer prevention and better overall health."Original article source: Weight-loss drugs' impact on cancer risk revealed in new study
Yahoo
13-05-2025
- Health
- Yahoo
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide). The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery. Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk. The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%). To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up. Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: 'Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.' Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m². Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma. Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms. GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes, including Alzheimer's disease, addictive disorders and psychiatric disorders. GLP-1RAs have grown massively in recent years following the release of Novo Nordisk's semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity, and Eli Lilly's tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity. GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales. GlobalData is the parent company of Clinical Trials Arena. "GLP-1RAs show anti-cancer benefits beyond weight loss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
13-05-2025
- Health
- Yahoo
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide). The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery. Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk. The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%). To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up. Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: 'Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.' Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m². Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma. Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms. GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes, including Alzheimer's disease, addictive disorders and psychiatric disorders. GLP-1RAs have grown massively in recent years following the release of Novo Nordisk's semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity, and Eli Lilly's tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity. GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales. GlobalData is the parent company of Clinical Trials Arena. "GLP-1RAs show anti-cancer benefits beyond weight loss" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
